About IntraOp Medical

1
About IntraOp Medical

• Co-founded in 1993 by Dr. Donald Goer
• Makers of the Mobetron, the first fully portable,
  self-shielding electron beam linear accelerator
• The Mobetron is used to administer intraoperative
  electron-beam radiation therapy (IOERT)
• 10 hospitals in North America have installed the
  Mobetron 23 are in use worldwide

2
IOERT and Breast Cancer

• IOERT gaining traction as cutting-edge treatment
  for breast cancer patients around the world
• Dr. Umberto Veronesi, Director of the European
  Institute of Oncology in Milan, Italy and
  world-renowned breast surgeon, has pioneered the
  use of IOERT for this purpose

3
Dr. Umberto Veronesi Background

• Dr. Veronesi has been a pioneering breast surgeon
  for nearly 40 years
• His clinical trials established breast conserving
  therapy rather than mastectomy as the
  standard of care for breast cancer patients
• His mission is to shift the breast cancer
  treatment paradigm from maximum tolerable
  treatment to minimum effective treatment

4
Dr. Umberto Veronesi Current Study

• Dr. Veronesis research studies using IOERT for
  breast cancer began in 1999 and more than 3200
  Italian women have taken part in it
• Dr. Veronesis current study seeks to determine
  whether women who receive breast-conserving
  surgery can have their post-surgical radiation
  reduced from the standard 6 weeks of daily
  radiation treatments to a 2-minute treatment of
  IOERT given at the time of surgery
• More than 1300 women have participated in this
  latest randomized trial

5
Study Results

• Dr. Veronesi presented the first findings of his
  randomized trial at the recent ISIORT conference
  in Madrid, Spain (June 2008)
• Patients were divided into two groups that
  received one of two types of treatment
• Breast conserving surgery and a single dose of
  IOERT
• Breast conserving surgery and traditional 6 weeks
  of post-operative radiation therapy
• Dr. Veronesis study reported that, to date,
  women who received a single dose of IOERT had
  identical control, survival and comestic results
  as those who underwent the standard 6 week
  radiation regimen

6
The Bombshell

• A single dose of IOERT may be equivalent in
  outcome to 6 weeks of post-operative radiation
  therapy.
• Many women can be successfully treated with
  IOERT rather than undergo a long course of
  radiation therapy.

7
What are the Benefits of Single-Dose IOERT?

• Single-dose radiation treatment means single-day
  treatment
• Patients get back to their lives more quickly
• Patients are spared the expense, time, and
  trouble of 6 weeks of daily radiation
• Patients can have oncoplastic reconstruction at
  the time of surgery rather than have to return
  many months later for a second surgery
• IOERT gives doctors an edge on treating cancer
• Doctors can apply radiation to the exact area
  that requires treatment, avoiding healthy tissue
• Doctors dont have to wait until a patient heals
  to deliver life-saving radiation

8
Where Can Breast Cancer Patients Receive
Single-Dose IOERT Treatment?

• Single-dose IOERT treatment for breast cancer is
  widely available in Europe and Asia
• There is only one facility in the United States
  that offers single-dose IOERT breast cancer
  treatment
• The University of North Carolina Lineberger
  Comprehensive Cancer Center uses IntraOps
  Mobetron to administer single-dose IOERT to
  breast cancer patients

9
Why Arent More American Hospitals Offering
IOERT Treatment?

• Cost
• American hospitals do not want to pay for
  additional devices that they are not certain they
  will quickly break even on
• American hospitals are not certain insurance
  companies will cover the treatment
  sufficiently, or at all
• Knowledge
• Many American doctors have been waiting for the
  results of the Veronesi randomized trials before
  considering adopting this technique
• Availability
• IOERT equipment is not yet widely available in
  the United States

10
Available for Comment

• As manufacturers of the only machine in the
  United States capable of delivering single-dose
  IOERT to breast cancer patients, IntraOp Medical
  is poised to answer questions and comment on Dr.
  Veronesis recent findings.
• IntraOp Medicals founder, Dr. Donald Goer, as
  well as representatives from the University of
  North Carolina Lineberger Comprehensive Cancer
  Center, are available for comment. A patient who
  recently received single-dose IOERT from the
  Mobetron at UNC is also available for comment.

11
Spokespeople

• IntraOp Medical
• Dr. Donald Goer, Founder and Chief Scientist
• John Powers, CEO
• The University of North Carolina Lineberger
  Comprehensive Cancer Center
• Dr. Joel Tepper, Professor and Chair of Radiation
  Oncology
• Dr. David Ollila, Associate Professor and
  Surgical Director for the Multidisciplinary
  Breast program and Multidisciplinary Melanoma
  Program
• Patient
• Arleen Sharwell, single-dose IOERT breast cancer
  patient at the University of North Carolina
  Lineberger Comprehensive Cancer Center

12
Additional Resources I

• Biographies
• Dr. Donald Goer
• Dr. Joel Tepper
• Dr. David Ollila
• Case Study
• Arleen Sharwell
• Video
• Interview with Dr. Umberto Veronesi from the
  European Society of Surgical Oncology meeting
  (2006)
• Mobetron in use at the Ohio State University
  Comprehensive Cancer Center

13
Additional Resources II

• Other documents
• Single-dose treatment brochure
• IOERT breast cancer brochure
• Nagoya University in Japan announces single-dose
  IOERT treatment program for breast cancer
  patients

14
For More Information

• Media Contact
• Regina Nisita
• Affect Strategies
• 212.398.9680 x145
• rnisita_at_affectstrategies.com
• Corporate Contact
• Wink Jones
• IntraOp Medical
• wjones_at_intraopmedical.com
• 303.447.1709